Epstein–Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course

摘要: Posttransplant lymphoproliferative disease (PTLD) is closely linked to primary Epstein-Barr virus (EBV) infection. A defect of EBV specific cellular immunity postulated play a pivotal role in the etiology PTLD, but there some debate as whether load peripheral blood transplant patients predicts onset PTLD or relapse after treatment. The current prospective, single-center study was undertaken investigate impact therapy on adult with PTLD. Fifteen solid organ transplantation were included and these, seven had EBV-associated All 15 received Rituximab therapy. In cases treatment failure treatment, polychemotherapy according cyclophosphamide, vincristine, doxorubicin, prednisone regimen. At median higher than no associated After therapy, four achieved long-lasting complete remissions. However, two these patients, increased reach levels high those recorded at Another patient showed dramatic decline first dose while suffering from progressive disease. other relapsed monotherapy, his viral stayed low. total, discordance clinical course observed five We conclude that does not correlate response suitable predictive marker for relapse.